Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1954 1
1957 1
1963 1
1975 4
1976 1
1978 4
1979 1
1980 4
1981 2
1982 1
1983 2
1985 1
1987 1
1988 1
1990 1
1993 2
1994 6
1995 16
1996 10
1997 13
1998 14
1999 14
2000 2
2001 2
2002 3
2003 4
2004 3
2005 2
2006 3
2007 6
2008 6
2009 5
2010 5
2011 19
2012 17
2013 10
2014 9
2015 16
2016 6
2017 10
2018 5
2019 7
2020 6
2021 8
2022 14
2023 9
2024 18
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: moore rg. Nat Med. 2025 Mar 5. doi: 10.1038/s41591-025-03566-1. Online ahead of print. Nat Med. 2025. PMID: 40044930
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
Kim K, Khazan N, McDowell JL, Snyder CWA, Miller JP, Singh RK, Whittum ME, Turner R, Moore RG. Kim K, et al. Among authors: moore rg. PLoS One. 2024 Dec 2;19(12):e0314564. doi: 10.1371/journal.pone.0314564. eCollection 2024. PLoS One. 2024. PMID: 39621651 Free PMC article.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. Among authors: moore rg. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. J Clin Oncol. 2025. PMID: 39591551 Free PMC article. Clinical Trial.
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Lee JM, et al. Among authors: moore rg. J Clin Oncol. 2024 Dec 20;42(36):4305-4316. doi: 10.1200/JCO.24.00683. Epub 2024 Oct 3. J Clin Oncol. 2024. PMID: 39361946 Clinical Trial.
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. Monk BJ, et al. Among authors: moore rg. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284381 Free article. Clinical Trial.
Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations.
Ciccioli M, Kim K, Khazan N, Khoury JD, Cooke MJ, Miller MC, O'Shannessy DJ, Pailhes-Jimenez AS, Moore RG. Ciccioli M, et al. Among authors: moore rg. J Exp Clin Cancer Res. 2024 Aug 21;43(1):240. doi: 10.1186/s13046-024-03149-x. J Exp Clin Cancer Res. 2024. PMID: 39169412 Free PMC article.
Realization of a two-dimensional Weyl semimetal and topological Fermi strings.
Lu Q, Reddy PVS, Jeon H, Mazza AR, Brahlek M, Wu W, Yang SA, Cook J, Conner C, Zhang X, Chakraborty A, Yao YT, Tien HJ, Tseng CH, Yang PY, Lien SW, Lin H, Chiang TC, Vignale G, Li AP, Chang TR, Moore RG, Bian G. Lu Q, et al. Among authors: moore rg. Nat Commun. 2024 Jul 17;15(1):6001. doi: 10.1038/s41467-024-50329-6. Nat Commun. 2024. PMID: 39019865 Free PMC article.
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
Graybill WS, Pardo Búrdalo B, O'Malley DM, Vergote I, Monk BJ, Auranen A, Copeland LJ, Sabbatini R, Herzog TJ, Follana P, Pothuri B, Braicu EI, McCormick C, Yubero A, Moore RG, Vuylsteke P, Raaschou-Jensen N, York W, Hartman J, González-Martín A. Graybill WS, et al. Among authors: moore rg. Int J Gynecol Cancer. 2024 Jul 1;34(7):1041-1050. doi: 10.1136/ijgc-2024-005356. Int J Gynecol Cancer. 2024. PMID: 38950925 Free PMC article. Clinical Trial.
276 results